Sana Biotechnology, Inc. Employee Directory
Biotechnology ResearchWashington, United States201-500 Employees
Sana Biotechnology, Inc. is a mid-sized biotechnology research company focused on medicines derived from engineered cells. It aims to push the boundaries of cell- and gene-therapy by enabling gene modification and the use of cells as therapeutic agents. Founded in 2019, the company is based in Seattle, Washington, with research operations in Seattle, Cambridge, and South San Francisco. Its focus is on patients with limited treatment options and prospects for untreatable progression, working with partners to advance therapies. A notable development is Sana's strategic collaboration with Mayo Clinic announced in 2026 to advance the hypoimmune-modified pancreatic islet cell therapy SC451 for type 1 diabetes.